iShares MSCI Japan ETF vs Zoetis Inc — how do they compare? iShares MSCI Japan ETF trades at $92.08, while Zoetis Inc trades at $76.65 (market cap $31.25B). The key difference: Zoetis Inc pays a 2.84% dividend while iShares MSCI Japan ETF pays none, and iShares MSCI Japan ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| EWJ | ZTS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $96.97 | $156.76 |
52-Week Low | $71.81 | $71.91 |
Market Cap | — | $31.25B |
Enterprise Value | — | $38.54B |
Dividend Yield | — | 2.84% |
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $91.98, down 2.03% on the day. The technical outlook is bullish based on moving averages, with oscillators neutral. Key support lies at $92-$93 and resistance at $94-$95. Recent news highlights Japan's market dynamics, including currency intervention risks and pension fund shifts.
The ETF offers exposure to Japanese equities amid a weakening yen and potential government support. Risks include yen volatility and economic sensitivity. Analyst sentiment is mixed, with technical strength offset by currency and macroeconomic uncertainties.
ZTS trades at $74.08, down 1.74% on the day, with a bearish technical signal from moving averages. The company reported strong 2025 results including $9.47B revenue, $2.67B net income, and a 28.03% net margin, but missed Q1 2026 EPS estimates. Recent news highlights a securities class action lawsuit and the launch of Lenivia in Canada and the EU.
Despite near-term legal overhangs and a recent earnings miss, ZTS maintains robust profitability and a consensus price target of $101.43 implies significant upside. Key risks include litigation outcomes and competitive pressures in the companion animal segment, while solid cash flow and high ROE support long-term value.
Trailing returns across standard periods
Latest headlines on both assets
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →